Marvel Biosciences Corp. (TSXV:MRVL)
Canada · Delayed Price · Currency is CAD 0.1750
+0.0050 (2.86%)
Aug 1, 2025, 3:53 PM EDT
Marvel Biosciences Company Description
Marvel Biosciences Corp., a biotechnology company, develops synthetic chemical derivatives of the original approved drug for the new disease indication in Canada.
The company’s lead compound MB-204, a novel fluorinated derivative of istradefylline, an adenosine A2a receptor antagonist to treat alzheimer’s disease and autism spectrum disorder, as well as depression and anxiety, ADHD, non-neurological conditions of cancer, and non-alcoholic steatohepatitis.
It provides non-hallucinogenic neuroplasticity program. The company is headquartered in Calgary, Canada.
Marvel Biosciences Corp.
| Country | Canada |
| Industry | Biotechnology |
| Sector | Healthcare |
| CEO | J. Matheson |
Contact Details
Address: 505 8th Avenue S.W. Calgary, Alberta T2P 1G2 Canada | |
| Phone | 403 770 2469 |
| Website | marvelbiotechnology.com |
Stock Details
| Ticker Symbol | MRVL |
| Exchange | TSX Venture Exchange |
| Fiscal Year | August - July |
| Reporting Currency | CAD |
| ISIN Number | CA57384M1077 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| J. Roderick Matheson | Executive Chairman and Chief Executive Officer |
| Dr. Mark Williams M.B.A., Ph.D. | President, Chief Science Officer and Director |
| Harpreet Nijjar C.M.A., CPA | Chief Financial Officer |
| Jacqueline Groot | Corporate Secretary |